Developer docs
API playgroundTry for free, no card

Search company profiles

Nanosonics

Full company profile

uuid000bbq4

Namestring
Nanosonics
Legal namestring
Nanosonics Limited
Company typeenum
Public
Founded yearint
2007
Descriptiontext

Nanosonics is an Australian-listed (ASX: NAN) infection prevention medical device company that develops automated high-level disinfection (HLD) systems for ultrasound probes and endoscopes. Its core platform, the trophon family (EPR, trophon2, trophon3), uses sonically activated hydrogen peroxide mist to deliver bedside-safe, enclosed high-level disinfection with validated compatibility across more than 1,000 probes from 30 global ultrasound manufacturers. The newer CORIS system extends the same automation philosophy into endoscope reprocessing, with regulatory clearances secured in Australia, the EU, and the UK and a first FDA 510(k) submission completed. Digital traceability modules (AcuTrace, AuditPro) integrate disinfection records into DICOM/PACS and cloud systems for audit-ready compliance.

Nanosonics makes money through a razor-and-blade model: an initial hardware sale of a trophon device, followed by recurring consumables revenue from proprietary hydrogen peroxide cartridges and accessories, supplemented by service and validation contracts. In H1 FY26, recurring consumables revenue was $75.7M out of $102.2M total revenue, and the installed base reached 38,080 devices globally. Management is guiding to $215-223M for full-year FY26, representing 8-12% growth at constant currency, with 20% unit installation growth in H1 FY26 and a 27% operating margin expansion driven by cost discipline. The company is debt-free with $159.8M cash.

Go-to-market is primarily direct enterprise field sales led by Regional Presidents in North America (Bill Haydon, joined December 2025), EMEA (Ronan Wright), Asia Pacific (Kimberly Hill, joined August 2025 as CMO and APAC President), and Japan (Katsumi Maruyama, President of Nanosonics Japan K.K.), supported by group purchasing organization agreements — most notably a new national contract with Premier, Inc. effective March 1, 2026 covering approximately 4,350 US hospitals. The company is ISO 27001 certified, GDPR/CCPA/HIPAA compliant, and serves acute care hospitals, outpatient clinics, and diagnostic imaging centers across Australia, New Zealand, Japan, the US, Canada, the UK, Ireland, France, and Germany.

Short descriptiontext

Nanosonics is an Australian-listed medical device company that sells automated high-level disinfection systems (trophon for ultrasound probes, CORIS for endoscopes) and proprietary hydrogen peroxide consumables to hospitals and clinics across nine countries, monetizing via a razor-and-blade model.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLane Cove, Australia
HQ citystring
Lane Cove
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
infection prevention devices, ultrasound probe disinfection, high-level disinfection systems, endoscope reprocessing equipment, medical device sterilization
Industry1 code
PRIMARYHLAHANAD
Disinfection & Surface Decontamination (Wipes, Sprays, Fogging, UV Robots)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Sterilization, Infection Prevention & Medical Disposables
NAICS code2 codes
  • Medical Equipment and Supplies Manufacturing3391
  • Soap, Cleaning Compound, and Toilet Preparation Manufacturing3256
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Specialty Cleaning, Polishing And Sanitation Preparations2842
Product category
Medical Device Infection Prevention
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Device Sales (trophon family)
TypeHardware Sales
Description

Sale of trophon2, trophon3, and related hardware devices for ultrasound probe disinfection. Device sales represent initial customer acquisition with recurring consumables revenue following.

investing.com
2Consumables (Recurring)
TypeSubscription Recurring
Description

Recurring revenue from hydrogen peroxide disinfectant cartridges and accessories. With over 38,000 devices installed globally, consumables generate predictable recurring revenue. Recurring revenue was $75.7 million in H1 FY26.

investing.com
3Service and Validation
TypeProfessional Services
Description

Service contracts, validation support, and maintenance services for installed device base.

nanosonics.com.au
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Enterprise pricing through group purchasing organizations
ModelOtherBilling cadenceMulti-year contract
Notes

Special pricing available through Premier, Inc. national group purchasing agreement for trophon3 device. Specific pricing not publicly disclosed.

prnewswire.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1trophon
Description

Automated high-level disinfection system for ultrasound probes using sonically activated hydrogen peroxide mist technology; includes trophon EPR, trophon2, and trophon3 models

nanosonics.com.au
+6 more records
Core offering1 text field

Nanosonics designs, manufactures, and sells automated high-level disinfection (HLD) systems for ultrasound probes (trophon EPR, trophon2 Plus, trophon3) and endoscope reprocessing (CORIS), supported by proprietary hydrogen peroxide disinfectant cartridges (NanoNebulant/Sonex-HL) and digital traceability software (AcuTrace, AuditPro). The systems use sonically activated hydrogen peroxide mist to deliver fully enclosed, bedside-safe HLD for healthcare facilities, with recurring revenue generated through consumable cartridge replacement. Customers include acute care hospitals, outpatient clinics, diagnostic imaging centers, and healthcare systems across North America, Europe, the Middle East, Africa, and Asia Pacific.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 9% revenue growth in H1 FY26 to $102.2 million
+5 more records
Product overview1 text field

Nanosonics offers a unified portfolio of infection prevention solutions centered on its trophon technology platform. The core offering consists of trophon devices (trophon EPR, trophon2 Plus, and trophon3) which provide automated high-level disinfection (HLD) for ultrasound probes using sonically activated hydrogen peroxide mist. These devices share the same core technology and are complemented by the newer CORIS endoscope reprocessing system. Supporting the device portfolio are digital traceability modules (AcuTrace and AuditPro) that provide automated compliance reporting and integration with DICOM/PACS systems. The company also provides consumables (hydrogen peroxide cartridges) and service/validation support. The trophon3 represents the latest generation with enhanced digital traceability features, while CORIS expands the portfolio into the endoscope reprocessing market.

Product and service6 records
1trophon3
CategoryAutomated high-level disinfection device
Description

Automated high-level disinfection (HLD) system for ultrasound probes with integrated digital traceability. Uses hydrogen peroxide mist and ultrasonic vibrations to kill bacteria, fungi, and viruses. Features DICOM and cloud integration for audit-ready compliance reporting. Designed for hospitals, outpatient clinics, and diagnostic imaging centers.

2trophon2 Plus
CategoryAutomated high-level disinfection device
Description

Automated high-level disinfection device for ultrasound probes using sonically activated hydrogen peroxide technology. Provides consistent and effective HLD with minimal hands-on time for healthcare facilities performing ultrasound-based diagnostics and procedures.

3trophon EPR
CategoryAutomated high-level disinfection device
Description

Original automated disinfection device for intracavity and surface ultrasound probes using ultrasonic vibrations and hydrogen peroxide mist technology to kill bacteria, fungi, and viruses. Designed for healthcare facilities performing endocavitary and surface ultrasound procedures.

4CORIS Endoscope Reprocessing System
CategoryEndoscope reprocessing system
Description

Next-generation endoscope reprocessing system designed to reduce process variability and support reliable, repeatable cleaning results every single cycle. Uses automated technology for consistent endoscope decontamination. Regulatory certifications secured in Australia, EU, and UK with first FDA 510(k) submission completed.

5trophon Consumables
CategoryDisinfectant consumables
Description

Proprietary hydrogen peroxide disinfectant cartridges and accessories for use with trophon devices. Includes enclosed disinfectant cartridges that are safe to handle with gloves. Recurring consumables revenue generated $75.7M in H1 FY26 across the 38,080 installed device base globally.

6Service & Validation
CategoryService and validation support
Description

Comprehensive service and validation support including installation, training, troubleshooting, and ongoing customer success support for installed trophon devices. Includes validation services to confirm HLD performance and regulatory compliance.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-01
Description

Nanosonics was awarded a national group purchasing agreement with Premier, Inc. for the trophon3 high-level ultrasound probe disinfection device, effective March 1, 2026. The agreement enables Premier member healthcare facilities to access special pricing and streamline procurement of the trophon3 device. Premier is a leading healthcare improvement company connecting approximately 4,350 U.S. hospitals and 325,000 other providers.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Steris
TypeDirect peer
Description

Steris is a global leader in sterilization and infection prevention with a broad portfolio spanning capital equipment, consumables, and services for hospitals and sterile processing departments. Following its acquisition of Cantel Medical, Steris is the most direct competitor to Nanosonics across ultrasound probe and endoscope reprocessing.

TypeDirect peer
Description

Cantel (now part of Steris) was a leading provider of infection prevention products, most notably Medivators endoscope reprocessing systems, directly competing with Nanosonics' CORIS launch. Several Nanosonics senior leaders (Bill Haydon, Gareth Daly) previously worked at Cantel, underscoring the competitive overlap.

3Wassenburg Medical
TypeDirect peer
Description

Wassenburg Medical is a specialist in endoscope reprocessing and infection prevention, directly competing with the CORIS platform in EMEA. Multiple Nanosonics EMEA executives (Ronan Wright, Gareth Daly) joined from Wassenburg, highlighting the close competitive and talent overlap.

TypeBroad incumbent
Description

ASP, a J&J MedTech subsidiary, is a global leader in low-temperature sterilization (Sterrad) and high-level disinfection for hospitals. Its portfolio overlaps with Nanosonics in HLD chemistries and instrument reprocessing workflows, making it a broad incumbent competitor for hospital infection-prevention budgets.

TypeBroad incumbent
Description

Getinge is a major Swedish provider of infection control, surgical workflow, and ICU solutions with a global hospital sales force. Its infection control business competes with Nanosonics' automated HLD and endoscope reprocessing offerings as part of a broader portfolio of sterilization and OR equipment.

TypeBroad incumbent
Description

Olympus is the dominant endoscope manufacturer and also offers endoscope reprocessing solutions (e.g., OER-Elite) through its medical systems business. As both a potential customer and competitor in endoscope reprocessing, Olympus is highly relevant to Nanosonics' CORIS launch.

TypeBroad incumbent
Description

Ecolab's Healthcare and Life Sciences segment provides infection prevention solutions including instrument chemistries, surface disinfection, and hand hygiene. While broader in scope, Ecolab overlaps with Nanosonics in healthcare disinfection chemistries and consumables sold to hospitals.

TypeBroad incumbent
Description

3M's Health Care division includes sterilization assurance, surgical solutions, and infection prevention products. As a diversified medtech incumbent with deep hospital relationships, 3M competes with Nanosonics for infection-prevention capital and consumables budgets.

TypeEmerging player
Description

Belimed, part of METTLER TOLEDO, specializes in infection prevention and sterilization equipment for hospitals and sterile processing. It competes with Nanosonics in automated washer-disinfectors and endoscope reprocessing, particularly in EMEA.

TypeOthers
Description

Cochlear is not a direct competitor but is highly relevant contextually: Nanosonics' CEO, COO, and CTO all previously held senior roles at Cochlear, and Nanosonics is frequently benchmarked against Cochlear as a comparable Australian-listed medical device commercial success story.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nanosonics

Medical Device Infection Preventionnanosonics.com.au

Nanosonics is an Australian-listed medical device company that sells automated high-level disinfection systems (trophon for ultrasound probes, CORIS for endoscopes) and proprietary hydrogen peroxide consumables to hospitals and clinics across nine countries, monetizing via a razor-and-blade model.

What Nanosonics does

Nanosonics is an Australian-listed (ASX: NAN) infection prevention medical device company that develops automated high-level disinfection (HLD) systems for ultrasound probes and endoscopes. Its core platform, the trophon family (EPR, trophon2, trophon3), uses sonically activated hydrogen peroxide mist to deliver bedside-safe, enclosed high-level disinfection with validated compatibility across more than 1,000 probes from 30 global ultrasound manufacturers. The newer CORIS system extends the same automation philosophy into endoscope reprocessing, with regulatory clearances secured in Australia, the EU, and the UK and a first FDA 510(k) submission completed. Digital traceability modules (AcuTrace, AuditPro) integrate disinfection records into DICOM/PACS and cloud systems for audit-ready compliance.

Nanosonics makes money through a razor-and-blade model: an initial hardware sale of a trophon device, followed by recurring consumables revenue from proprietary hydrogen peroxide cartridges and accessories, supplemented by service and validation contracts. In H1 FY26, recurring consumables revenue was $75.7M out of $102.2M total revenue, and the installed base reached 38,080 devices globally. Management is guiding to $215-223M for full-year FY26, representing 8-12% growth at constant currency, with 20% unit installation growth in H1 FY26 and a 27% operating margin expansion driven by cost discipline. The company is debt-free with $159.8M cash.

Go-to-market is primarily direct enterprise field sales led by Regional Presidents in North America (Bill Haydon, joined December 2025), EMEA (Ronan Wright), Asia Pacific (Kimberly Hill, joined August 2025 as CMO and APAC President), and Japan (Katsumi Maruyama, President of Nanosonics Japan K.K.), supported by group purchasing organization agreements — most notably a new national contract with Premier, Inc. effective March 1, 2026 covering approximately 4,350 US hospitals. The company is ISO 27001 certified, GDPR/CCPA/HIPAA compliant, and serves acute care hospitals, outpatient clinics, and diagnostic imaging centers across Australia, New Zealand, Japan, the US, Canada, the UK, Ireland, France, and Germany.

Nanosonics firmographics

Firmographics
Name
Nanosonics
Legal name
Nanosonics Limited
Website
https://nanosonics.com.au
Company type
Public
Founded year
2007
Operating status
Operating
Headcount range
101–250 employees
Short description
Nanosonics is an Australian-listed medical device company that sells automated high-level disinfection systems (trophon for ultrasound probes, CORIS for endoscopes) and proprietary hydrogen peroxide consumables to hospitals and clinics across nine countries, monetizing via a razor-and-blade model.
Ownership category
akta.pro rank

Nanosonics industry classification

Industry
Product category
Medical Device Infection Prevention
NAICS
Medical Equipment and Supplies Manufacturing (3391), Soap, Cleaning Compound, and Toilet Preparation Manufacturing (3256)
SIC
Surgical & Medical Instruments & Apparatus (3841), Specialty Cleaning, Polishing And Sanitation Preparations (2842)
akta.pro industry
PRIMARYHLAHANAD
Disinfection & Surface Decontamination (Wipes, Sprays, Fogging, UV Robots)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Sterilization, Infection Prevention & Medical Disposables

Keywords

  • Infection prevention devices
  • Ultrasound probe disinfection
  • High-level disinfection systems
  • Endoscope reprocessing equipment
  • Medical device sterilization

Where Nanosonics is headquartered

Location

Headquarters

HQ city
Lane Cove
HQ country
Australia
HQ region
Oceania

Offices6 records

Markets served

Nanosonics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Device Sales (trophon family): Sale of trophon2, trophon3, and related hardware devices for ultrasound probe disinfection. Device sales represent initial customer acquisition with recurring consumables revenue following.
  2. Consumables (Recurring): Recurring revenue from hydrogen peroxide disinfectant cartridges and accessories. With over 38,000 devices installed globally, consumables generate predictable recurring revenue. Recurring revenue was $75.7 million in H1 FY26.
  3. Service and Validation: Service contracts, validation support, and maintenance services for installed device base.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise pricing through group purchasing organizations

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Nanosonics product offering

Product offering

Core offering

Nanosonics designs, manufactures, and sells automated high-level disinfection (HLD) systems for ultrasound probes (trophon EPR, trophon2 Plus, trophon3) and endoscope reprocessing (CORIS), supported by proprietary hydrogen peroxide disinfectant cartridges (NanoNebulant/Sonex-HL) and digital traceability software (AcuTrace, AuditPro). The systems use sonically activated hydrogen peroxide mist to deliver fully enclosed, bedside-safe HLD for healthcare facilities, with recurring revenue generated through consumable cartridge replacement. Customers include acute care hospitals, outpatient clinics, diagnostic imaging centers, and healthcare systems across North America, Europe, the Middle East, Africa, and Asia Pacific.

Product overview

Nanosonics offers a unified portfolio of infection prevention solutions centered on its trophon technology platform. The core offering consists of trophon devices (trophon EPR, trophon2 Plus, and trophon3) which provide automated high-level disinfection (HLD) for ultrasound probes using sonically activated hydrogen peroxide mist. These devices share the same core technology and are complemented by the newer CORIS endoscope reprocessing system. Supporting the device portfolio are digital traceability modules (AcuTrace and AuditPro) that provide automated compliance reporting and integration with DICOM/PACS systems. The company also provides consumables (hydrogen peroxide cartridges) and service/validation support. The trophon3 represents the latest generation with enhanced digital traceability features, while CORIS expands the portfolio into the endoscope reprocessing market.

Differentiator

Problem solved

Functional benefit

Brands

  • trophon: Automated high-level disinfection system for ultrasound probes using sonically activated hydrogen peroxide mist technology; includes trophon EPR, trophon2, and trophon3 models
  • CORIS
  • AcuTrace
  • AuditPro
  • Nanosonics Academy
  • NanoNebulant
  • Sonex-HL

Products and services

  • trophon3 Automated high-level disinfection (HLD) system for ultrasound probes with integrated digital traceability. Uses hydrogen peroxide mist and ultrasonic vibrations to kill bacteria, fungi, and viruses. Features DICOM and cloud integration for audit-ready compliance reporting. Designed for hospitals, outpatient clinics, and diagnostic imaging centers.
  • trophon2 Plus Automated high-level disinfection device for ultrasound probes using sonically activated hydrogen peroxide technology. Provides consistent and effective HLD with minimal hands-on time for healthcare facilities performing ultrasound-based diagnostics and procedures.
  • trophon EPR Original automated disinfection device for intracavity and surface ultrasound probes using ultrasonic vibrations and hydrogen peroxide mist technology to kill bacteria, fungi, and viruses. Designed for healthcare facilities performing endocavitary and surface ultrasound procedures.
  • CORIS Endoscope Reprocessing System Next-generation endoscope reprocessing system designed to reduce process variability and support reliable, repeatable cleaning results every single cycle. Uses automated technology for consistent endoscope decontamination. Regulatory certifications secured in Australia, EU, and UK with first FDA 510(k) submission completed.
  • trophon Consumables Proprietary hydrogen peroxide disinfectant cartridges and accessories for use with trophon devices. Includes enclosed disinfectant cartridges that are safe to handle with gloves. Recurring consumables revenue generated $75.7M in H1 FY26 across the 38,080 installed device base globally.
  • Service & Validation Comprehensive service and validation support including installation, training, troubleshooting, and ongoing customer success support for installed trophon devices. Includes validation services to confirm HLD performance and regulatory compliance.

Quantifiable outcome

  • 9% revenue growth in H1 FY26 to $102.2 million
  • +5 more outcomes

Companies that use Nanosonics

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Nanosonics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

Feature3 records

Nanosonics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Premier, Inc.coreChannel Partner/ Reseller/ Distributor · 1 March 2026Nanosonics was awarded a national group purchasing agreement with Premier, Inc. for the trophon3 high-level ultrasound probe disinfection device, effective March 1, 2026. The agreement enables Premier member healthcare facilities to access special pricing and streamline procurement of the trophon3 device. Premier is a leading healthcare improvement company connecting approximately 4,350 U.S. hospitals and 325,000 other providers.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Nanosonics competitors and assessment

Company assessment

Direct peers

  • Steris: Steris is a global leader in sterilization and infection prevention with a broad portfolio spanning capital equipment, consumables, and services for hospitals and sterile processing departments. Following its acquisition of Cantel Medical, Steris is the most direct competitor to Nanosonics across ultrasound probe and endoscope reprocessing.
  • Cantel Medical: Cantel (now part of Steris) was a leading provider of infection prevention products, most notably Medivators endoscope reprocessing systems, directly competing with Nanosonics' CORIS launch. Several Nanosonics senior leaders (Bill Haydon, Gareth Daly) previously worked at Cantel, underscoring the competitive overlap.
  • Wassenburg Medical: Wassenburg Medical is a specialist in endoscope reprocessing and infection prevention, directly competing with the CORIS platform in EMEA. Multiple Nanosonics EMEA executives (Ronan Wright, Gareth Daly) joined from Wassenburg, highlighting the close competitive and talent overlap.

Broad incumbents

  • Advanced Sterilization Products (ASP, Johnson & Johnson): ASP, a J&J MedTech subsidiary, is a global leader in low-temperature sterilization (Sterrad) and high-level disinfection for hospitals. Its portfolio overlaps with Nanosonics in HLD chemistries and instrument reprocessing workflows, making it a broad incumbent competitor for hospital infection-prevention budgets.
  • Getinge: Getinge is a major Swedish provider of infection control, surgical workflow, and ICU solutions with a global hospital sales force. Its infection control business competes with Nanosonics' automated HLD and endoscope reprocessing offerings as part of a broader portfolio of sterilization and OR equipment.
  • Olympus: Olympus is the dominant endoscope manufacturer and also offers endoscope reprocessing solutions (e.g., OER-Elite) through its medical systems business. As both a potential customer and competitor in endoscope reprocessing, Olympus is highly relevant to Nanosonics' CORIS launch.
  • Ecolab: Ecolab's Healthcare and Life Sciences segment provides infection prevention solutions including instrument chemistries, surface disinfection, and hand hygiene. While broader in scope, Ecolab overlaps with Nanosonics in healthcare disinfection chemistries and consumables sold to hospitals.
  • 3M Health Care: 3M's Health Care division includes sterilization assurance, surgical solutions, and infection prevention products. As a diversified medtech incumbent with deep hospital relationships, 3M competes with Nanosonics for infection-prevention capital and consumables budgets.

Emerging players

  • Belimed (METTLER TOLEDO): Belimed, part of METTLER TOLEDO, specializes in infection prevention and sterilization equipment for hospitals and sterile processing. It competes with Nanosonics in automated washer-disinfectors and endoscope reprocessing, particularly in EMEA.

Others

  • Cochlear: Cochlear is not a direct competitor but is highly relevant contextually: Nanosonics' CEO, COO, and CTO all previously held senior roles at Cochlear, and Nanosonics is frequently benchmarked against Cochlear as a comparable Australian-listed medical device commercial success story.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Nanosonics social profiles

Digital presence

Nanosonics compliance and trust

Trust signal

Compliance4 records

Nanosonics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nanosonics leadership team

Management profile

Number of profiles

Profiles18 records

Nanosonics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Nanosonics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nanosonics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nanosonics

What does Nanosonics do?

Nanosonics designs, manufactures, and sells automated high-level disinfection (HLD) systems for ultrasound probes (trophon EPR, trophon2 Plus, trophon3) and endoscope reprocessing (CORIS), supported by proprietary hydrogen peroxide disinfectant cartridges (NanoNebulant/Sonex-HL) and digital traceability software (AcuTrace, AuditPro). The systems use sonically activated hydrogen peroxide mist to deliver fully enclosed, bedside-safe HLD for healthcare facilities, with recurring revenue generated through consumable cartridge replacement. Customers include acute care hospitals, outpatient clinics, diagnostic imaging centers, and healthcare systems across North America, Europe, the Middle East, Africa, and Asia Pacific.

Is Nanosonics a public or private company?

Nanosonics is a public company. It is classified as public and is currently operating.

When was Nanosonics founded?

Nanosonics was founded in 2007. It employs 101 to 250 people.

Where is Nanosonics based?

Nanosonics is headquartered in Lane Cove, Australia, in the Oceania region.

How does Nanosonics make money?

Three revenue lines are on record. Device Sales (trophon family) is the primary driver. The others are consumables (Recurring) and service and Validation.

Who are Nanosonics's main competitors?

Direct peers on record are Steris, Cantel Medical and Wassenburg Medical. Broad incumbents are Advanced Sterilization Products (ASP, Johnson & Johnson), Getinge, Olympus, Ecolab and 3M Health Care. Belimed (METTLER TOLEDO) is listed as an emerging player. Cochlear is listed as an others.

Does Nanosonics have an API?

No public API is recorded for Nanosonics.

What industry is Nanosonics in?

Nanosonics's product category is Medical Device Infection Prevention. Its primary akta.pro industry code is HLAHANAD, Disinfection & Surface Decontamination (Wipes, Sprays, Fogging, UV Robots). Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comNanosonics at Bell Potter Healthcare Conference: coris launch advancesNanosonics announced at the Bell Potter Healthcare Conference that its CORIS endoscope reprocessing system has cleared regulatory hurdles in the U.S., Europe, Australia, and New Zealand. The company plans a controlled market release in the U.S. and full commercialization in Europe and Australia, with FY2027 as a foundational investment year. Commercial traction is expected in FY2028.YahooDid Nanosonics' Fall Catch You Out? What Investors MissedNanosonics shares fell 29.4% over the past year, including dividends. H2 2026 revenue was A$101.662 million, but net margin slipped from 10.4% to 8.1%, undercutting margin expansion expectations. The stock now trades at A$2.83, below its starting price.Simply Wall StWhy Nanosonics Bears Were Right Before The DropNanosonics reported FY26 revenue of A$203.9m with 6% growth and a 76.9% gross margin, but H2 2026 revenue fell to A$101.7m and net margin dropped to 8.1%. The stock trades at A$2.89, below the A$4.27 starting price, with analysts expecting CORIS to become a second earnings engine.YahooNanosonics' CORIS® System wins Gold at the 2026 Australian Good Design AwardsNanosonics' CORIS System won a Gold award at the 2026 Australian Good Design Awards in the Product Design Medical and Scientific category. The system automates cleaning of flexible endoscopes before disinfection, addressing infection risk from inadequate cleaning. It received De Novo clearance from the FDA in 2025 and was included in the Australian Register of Therapeutic Goods.PR NewswireNanosonics' CORIS® System wins Gold at the 2026 Australian Good Design AwardsNanosonics' CORIS System won Gold at the 2026 Australian Good Design Awards in the Product Design Medical and Scientific category. The system automates cleaning of flexible endoscopes before disinfection, addressing manual cleaning variability. It received De Novo FDA clearance in 2025 and peer-reviewed research in 2024 confirmed superior cleaning performance.YahooNanosonics Ltd (NNCSF) (FY 2026) Earnings Call Highlights: Record Trophon Placements and CORIS ...Nanosonics reported FY26 revenue of $203.9 million, up 3% reported and 6% constant currency, with EBIT of $16 million, up 21% year-over-year. Trophon-only EBIT rose 16% to $50.6 million, while APAC revenue fell 14%. Management guided FY27 revenue to $220-228 million at constant currency.Seeking AlphaNanosonics Limited (NNCSF) Q4 2026 Earnings Call TranscriptNanosonics held its FY '26 full-year results investor briefing, with Catherine Strong, Head of Investor Relations and Corporate Communications, welcoming attendees. CEO Michael Kavanagh and CFO Jason Burriss were set to present slides lodged earlier that morning with the ASX, followed by a question-and-answer session. No financial figures were disclosed in the transcript.Investing.comNanosonics FY26 slides: core strength, CORIS launch costs weigh By Investing.comNanosonics reported FY26 results on August 25, 2026, with constant-currency revenue of $211.5 million, up 6%, and constant-currency EBIT of $21.6 million, up 21%, though reported EBIT fell 10% to $16.0 million. Shares dropped 14.4% to $3.15 as investors priced in margin compression and FY27 operating expense growth of 10-15%. Management guided to $220-228 million constant-currency revenue, with CORIS expected to contribute low single-digit millions.Investing.comNanosonics FY26 slides: trophon strength funds CORIS launch push By Investing.comNanosonics (ASX:NAN) reported FY26 results on August 25, 2026, with constant currency revenue up 6% to $211.5 million and EBIT up 21% to $21.6 million, though reported EBIT fell 10% to $16.0 million. Shares dropped 14.4% to $3.15 as investors weighed margin compression and a $40 million FY27 buyback. CORIS, cleared in the UK, Europe, Australia and the US, launches commercially in H1 FY27.